PTGS2 and central nervous system cancer: Several other studies, conducted with different selective COX-2 inhibitors (e.g., Meloxicam) on a panel of glioma cell lines (e.g., D384, U87, and U251), reconfirmed the rationale of targeting COX-2 to induce radiosensitization in brain cancer cells [92].